Table 1. Baseline Clinical Characteristics.
Variable | Non-HDL-Cholesterol (mg/dl) |
|||
---|---|---|---|---|
≦ 140 n = 38 | 141–169 n = 42 | ≧ 170 n = 39 | p value | |
Age years | 70.3 ± 8.8 | 67.0 ± 8.9 | 62.9 ± 11.6 | 0.006 |
Men | 33 (86.8%) | 33 (78.6%) | 33 (84.6%) | 0.62 |
Body mass index (kg/mm2) | 23.5 ± 2.8 | 23.9 ± 2.8 | 25.9 ± 4.3 | 0.004 |
Diabetes Mellitus | 14 (36.8%) | 15 (35.7%) | 21 (53.8%) | 0.19 |
Hypertension | 26 (68.4%) | 25 (59.5%) | 24 (61.5%) | 0.69 |
Treatment allocation | ||||
Pitavastatin | 21 (55.3%) | 19 (45.2%) | 18 (46.2%) | 0.62 |
Pravastatin | 17 (44.7%) | 23 (54.8%) | 21 (53.8%) | |
Stable angina pectoris | 30 (78.9%) | 31 (73.8%) | 22 (56.4%) | 0.077 |
Unstable angina pectoris | 8 (21.1%) | 11 (26.2%) | 17 (43.6%) | |
Target vessel | ||||
Left anterior descending | 23 (60.5%) | 22 (52.4%) | 22 (56.4%) | 0.72 |
Left circumflex | 1 (2.6%) | 1 (2.4%) | 3 (7.7%) | |
Right | 14 (36.8%) | 19 (45.2%) | 14 (35.9%) | |
Type of stent | ||||
Bare metal stent | 5 (13.2%) | 10 (23.8%) | 5 (12.8%) | 0.34 |
Drug-eluting stent | 33 (86.8%) | 32 (76.2%) | 34 (87.2%) | |
Medications | ||||
Aspirin | 37 (97.4%) | 41 (97.6%) | 39 (100%) | 0.77 |
Thienopyridine | 37 (97.4%) | 41 (97.6%) | 38 (97.4%) | 0.99 |
ACE-I or ARB | 23 (60.5%) | 18 (42.9%) | 20 (51.3%) | 0.29 |
β-blocker | 5 (13.2%) | 2 (4.8%) | 6 (15.4%) | 0.25 |
Calcium channel blocker | 23 (60.5%) | 20 (47.6%) | 17 (43.6%) | 0.30 |
Follow-up duration (days) | 236 ± 37 | 221 ± 35 | 225 ± 37 | 0.15 |
Values are means ± SDs or numbers (percentages); HDL, high-density lipoprotein; ACE-I indicates, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker